南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

半乳糖修饰LNP介导肝脏Sam68沉默通过抑制糖异生改善糖尿病葡萄糖稳态

Galactosylated LNP-mediated hepatic Sam68 silencing improves glucose homeostasis in diabetes by suppressing gluconeogenesis

Ning Wang, Xiang Cao, Jing Lai, Yifan Gao, Ao Yu, Siyu An, Yucheng Gao, Ebenezeri Erasto Ngowi, Juan Yang, Chang Fu, Junyu Xu, Li Tian, Haozhe Piao, Shiyang Shen, Aijun Qiao

Journal:JOURNAL OF NANOBIOTECHNOLOGY

IF:12.6

DOI:10.1186/s12951-026-04511-1

PMID:

Published:2026-05-14

research field:RNA干扰药物递送系统分子代谢糖尿病研究纳米医学

Abstract

Excessive hepatic glucose production is a key driver of the progression of type 2 diabetes (T2DM), a highly prevalent global metabolic disorder. We previously reported that Sam68 expression is upregulated in the livers of both diabetic patients and mouse models, and hepatocyte-specific knockdown of Sam68 greatly alleviates hyperglycemia and improves insulin sensitivity in diabetic mice. Here, we engineered a series of ligand-functionalized lipid nanoparticles (LNPs) and identified a galactose-decorated formulation (LNP-Gal) that enables efficient hepatocyte-selective delivery of Sam68 siRNA, thereby achieving robust Sam68 silencing and suppressing hepatic gluconeogenesis in both cellular and animal models. In both genetic and diet-induced diabetic mouse models, systemic administration of siSam68/LNP-Gal improved glycemic control and insulin responsiveness and attenuated hepatic gluconeogenic output, accompanied by suppression of the hepatic gluconeogenic program. Thus, we establish siSam68/LNP-Gal as a hepatocyte-selective siRNA delivery system that elicits a potent antihyperglycemic effect with a favorable safety profile in vitro and in vivo, providing a promising siRNA-based strategy for the treatment of T2DM and related metabolic disorders.

本文使用的Yeasen产品

购物车
客服
转染试用